Global Public Health Portfolio

The World Health Organization, Coalition for Epidemic Preparedness, and the National Institute of Allergy and Infectious Diseases of the United States National Institute of Health have published lists of their priority pathogens, including emerging threats and neglected diseases. 

The mRNA Access program will offer researchers use of Moderna’s mRNA technology to target these identified priority pathogens to accelerate the development of medicines to prevent these diseases.

Pathogen
ID #
Preclinical Development
Phase 1
Phase 2
Phase 3
Commercial
Collaborators

PRIORITY PATHOGENS

COVID-19
mRNA-1273
Commercial
BARDA/NIAID
Zika
mRNA-1893
Phase 2
BARDA
Chikungunya
mRNA-1388
Phase 1
--
HIV
mRNA-1574
Phase 1
IAVI/BMGF/NIAID & Others
HIV
mRNA-1644
Phase 1
IAVI/Others
Mpox
mRNA-1769
Phase 1
--
Nipah
mRNA-1215
Phase 1
NIH
Pandemic Flu
mRNA-1018
Phase 1
--
Dengue
--
Preclinical Development
--

Permitted Pathogens

Argentinian mammarenavirus (Junin virus)
Bartonella
Bunyavirus la crosse
Burkholderia mallei
Burkholderia pseudomallei 
Cache Valley virus
Caliciviruses
California encephalitis virus
Campylobacter jejuni
Canine Distemper
Cedar henipa virus
Chapare virus
Chikungunya virus
Chlamydia psittaci
Clostridium botulinum toxin
Coccidioides species
Coxiella burnetii
Crimean-Congo hemorrhagic fever virus
Cryptosporidium parvum
Cyclospora cayatanensis
Deer tick virus
Dengue virus
Eastern equine encephalitis virus
Ebola virus
Echovirus
Entamoeba histolytica
Enterovirus A71
Enterovirus D68
Escherichia coli (ETEC, STEC, EPEC)
Escherichia coli (UPEC)
Flavivirus powassan
Francisella tularensis
Ghanaian bat henipavirus (Kumasi virus)
Giardia lamblia
Group A Streptococcaceae
Group B Streptococcaceae
Guanarito virus
Hantaan virus
Hantaviruses causing Hanta Pulmonary syndrome
Hazara virus
Hendra virus
Hepatitis A, C, E virus
Human immunodeficiency virus
Human parainfluenza 1 virus (HPIV-1)
Human parainfluenza 3 virus (HPIV-3)
Human T-cell leukaemia virus type 1
Influenza virus A (Pandemic)
Japanese encephalitis virus
Klebsiella pneumoniae
Kyasanur Forest virus
LaCrosse encephalitis virus
Lake Victoria marburgvirus-Ravn
Lassa virus
Leishmaniasis
Leptospirosis
Listeria monocytogenes
Lujo virus
Lymphocytic choriomeningitis virus
Machupo virus
Marburg virus
Mayaro virus
Menagle virus
Meningocococcal meningitis
Microsporidia
Middle East respiratory syndrome coronavirus
Mojiang virus
Monkeypox virus
Mycobacterium tuberculosis
Mycobacterium ulcerans
Naegleria fowleri
Necator americanus (New World Hookworm)
Neisseria gonorrhoeae
Neisseria meningitidis
Nipah virus
Norovirus
O'nyong-nyong virus
Omsk hemorrhagic fever virus
Orthohantavirus
Phlebovirus
Plasmodium species
Punta Toro virus
Rabies virus
Ravn virus
Rhinovirus C
Ricin toxin (Ricinus communis)
Rickettsia species
Rift Valley fever virus
Salmonella (typhoid/paratyphoid fever)
SARS-associated coronavirus
Schistosoma species
Seasonal Influenza
Semliki Forest virus
Severe fever with thrombocytopenia syndrome virus
Shigella species
Sin Nombre virus
Sosuga virus
St. Louis encephalitis virus
Staphylococcus enterotoxin B
Toxoplasma gondii
Trypanosoma cruzi
Variola virus
Venezuelan equine encephalitis virus
Vibrio (pathogenic)
West Nile virus
Western equine encephalitis virus
Yellow fever virus
Yersinia pestis
Zika virus

Interested in mRNA Access?

Partner with us to bring this global health initiative to life.

By submitting your information, you agree to Moderna’s Terms and Conditions. You also acknowledge that your information will be processed in accordance with Moderna’s Privacy Policy.

To help protect this form from spam and abuse, Moderna uses automated security controls.